# Hiroaki Kobayashi > Hiroaki Kobayashi is a Series A investor at UTEC - The University of Tokyo Edge Capital Partners backing Medical. See 5 investments, check sizes, portfolio… - Type: Angel Investor - Fund: [UTEC - The University of Tokyo Edge Capital Partners](https://shizune.co/investors/profile/utec) - Location: Tokyo, Japan - Total investments: 5 - Last investment: Jan 2026 - Lead investor: 60% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/hkoby/ Hiroaki Kobayashi is a Principal at UTEC. He attended the University of Michigan - Stephen M. Ross School of Business. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Medical | 4 | 80% | | Health Care | 4 | 80% | | Biotechnology | 2 | 40% | | Energy | 1 | 20% | | Big Data | 1 | 20% | 10 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series A | 2 | 40% | | Series B | 2 | 40% | | Series C | 1 | 20% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Power Wave | Power Wave seeks a carbon-neutral world using wave technology for wireless power, tackling global warming and fuel depletion. | $5.9M | Series A | Jan 30, 2026 | | | Cellusion | Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system. | $20.3M | Series C | Jun 06, 2023 | | | Medcom | Frontier Field is a venture company that brings the medical and healthcare fields together with the power of IT. It also engaged in the planning, development, sales, and maintenance of the nibyo mobile smartphone exclusively for medical institutions. | $7.4M | Series B | Jun 08, 2022 | | | Metcela | Metcela is a clinical-stage biotech startup providing patients with an innovative and alternative treatment option for heart disease. The company's lead asset, MTC001 is a cell therapy based on VCAM-1-positive Cardiac Fibroblast (VCF) that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies.Metcela's therapy uses a specific fibroblast cell that is obtained from the patient's heart and instead of replacing them, it repairs the damage by enhancing the cells' ability to heal, providing patients with an effective and reasonably-priced cure for heart failure.It was founded on March 9, 2016, and is headquartered in Kawasaki, Japan. | $12.7M | Series B | Jan 04, 2021 | | | TXP Medical | TXP Medical build a next-generation medical system through acute care. | $2.3M | Series A | Jul 06, 2020 | | 5 of 5 investments shown. ## Co-investors - [Alfresa Holdings](https://shizune.co/investors/profile/alfresa-holdings) — VC Fund, 2 deals together - [Archetype Ventures](https://shizune.co/investors/profile/archetype-ventures) — VC Fund, 2 deals together - [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund, 2 deals together - [AIS CAPITAL](https://shizune.co/investors/profile/ais-capital) — VC Fund, 1 deal together - [Axil Capital](https://shizune.co/investors/profile/axil-capital) — VC Fund, 1 deal together - [Dai-ichi Life](https://shizune.co/investors/profile/dai-ichi-life) — VC Fund, 1 deal together ## About UTEC - The University of Tokyo Edge Capital Partners VC Fund · Tokyo, Japan UTEC - The University of Tokyo Edge Capital Partners, is a Japan-based seed/early stage deep-tech venture capital firm associated with academic institutes such as The University of Tokyo. UTEC has over $1 billion in Assets Under Management, and has invested in 150+ companies in Japan, USA, Singapore, India and Europe with a track record of 20IPOs and 22 successful M&A (as of Nov 2025). UTEC predominantly invests in three deep-tech sectors: a) Healthcare & Life Sciences, b) IT/AI, and c) Physical Sciences & Engineering. 5 contacts available at UTEC - The University of Tokyo Edge Capital Partners. | Name | Title | Profile | | --- | --- | --- | | Atsushi Usami | Partner & Board Director | https://shizune.co/investors/profile/atsushi-usami | | Hiroaki Kobayashi | Principal | https://shizune.co/investors/profile/hiroaki-kobayashi-3588 | | Keisuke Ide | Partner | https://shizune.co/investors/profile/keisuke-ide | | Kiran Mysore | Principal | https://shizune.co/investors/profile/kiran-mysore | | Maiko Katadae | Partner | https://shizune.co/investors/profile/maiko-katadae | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund ## FAQ ### What does Hiroaki Kobayashi invest in? Hiroaki Kobayashi invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Hiroaki Kobayashi last invest? The most recent investment recorded for Hiroaki Kobayashi closed in Jan 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co